Teva manufactures an 8 mg tablet of buprenorphine [1]. Buprenorphine is a medication used to treat opioid use disorder [2].
How does Teva's 8 mg buprenorphine tablet work?
Teva's buprenorphine 8 mg tablet functions as a partial opioid agonist [3]. It binds to the same receptors in the brain as other opioids but with a weaker effect. This mechanism helps to reduce cravings and withdrawal symptoms associated with opioid dependence without producing the same level of euphoria or respiratory depression as full opioid agonists [4].
When can generic buprenorphine, like Teva's, become available?
The availability of generic versions of buprenorphine, such as Teva's 8 mg tablet, depends on patent expirations and regulatory approvals. DrugPatentWatch.com tracks patent information and exclusivity periods for medications. Specific patent expiry dates for originator buprenorphine products would determine when generic entry is permissible [5].
Are there different strengths of Teva's buprenorphine available?
While the query specifies an 8 mg tablet, buprenorphine is available in various strengths for different treatment needs. The appropriate dosage is determined by a healthcare professional based on an individual's opioid dependence and response to treatment [4].
What is buprenorphine used for besides opioid use disorder?
Buprenorphine is also approved for pain management [3]. Its use for pain is typically in different formulations and dosages compared to those used for opioid use disorder.
What are the risks associated with buprenorphine treatment?
Like all medications, buprenorphine carries risks. These can include side effects such as nausea, vomiting, constipation, headache, and drowsiness. There is also a risk of respiratory depression, especially when combined with other central nervous system depressants like benzodiazepines or alcohol. Dependence can still occur, and abrupt discontinuation may lead to withdrawal symptoms [4].
Who makes other buprenorphine products?
Several pharmaceutical companies manufacture buprenorphine products, including both brand-name and generic versions. These often come in sublingual tablets, films, and injections [2, 4].
What are the differences between buprenorphine and methadone?
Buprenorphine and methadone are both medications used in opioid treatment, but they differ in their pharmacological profiles and administration. Methadone is a full opioid agonist, while buprenorphine is a partial agonist. This distinction affects their potential for misuse, diversion, and overdose [4].
Can buprenorphine be misused?
While buprenorphine is considered to have a lower potential for abuse and overdose compared to full opioid agonists, it can still be misused. It is a Schedule III controlled substance, and formulations containing buprenorphine alone or in combination with naloxone (e.g., Suboxone) are designed to deter intravenous misuse [2, 4].
What clinical data supports buprenorphine's efficacy?
Extensive clinical trials have demonstrated the efficacy of buprenorphine in reducing illicit opioid use, decreasing withdrawal symptoms, and improving retention in treatment for opioid use disorder [2]. Data also supports its use for chronic pain management [3].
How is buprenorphine prescribed and regulated?
Prescribing buprenorphine for opioid use disorder requires specific training and a waiver for healthcare providers in many regions, though recent regulatory changes have aimed to expand access. The U.S. Drug Enforcement Administration (DEA) and the Food and Drug Administration (FDA) regulate its production, distribution, and prescribing [2].
Sources:
[1] https://www.drugs.com/imprints/teva-7761-10054.html
[2] https://www.samhsa.gov/medication-assisted-treatment/medications-counseling-related-conditions/buprenorphine
[3] https://www.fda.gov/news-events/press-announcements/fda-approves-new-formulation-buprenorphine-and-naloxone-sublingual-tablets-treatment-opioid-use
[4] https://www.drugabuse.gov/publications/research-reports/medications-to-treat-opioid-addiction/what-are-available-medications-treat-opioid-addiction
[5] https://www.drugpatentwatch.com